We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+4.4%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$6.84M
Cap. Flow
+$260K
Cap. Flow %
0.15%
Top 10 Hldgs %
93.51%
Holding
17
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$11.6M

Top Sells

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$6.18M
2
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$5.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.76B
$54.9M 32.61%
1,237,202
– –
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$52.5M 31.22%
219,901
-28,148
-11% -$6.18M
VRNA
3
DELISTED
Verona Pharma
VRNA
$11.3M 6.7%
+901,943
New +$11.6M
PRTK
4
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10M 5.97%
1,041,131
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$7.94M 4.72%
440,000
– –
CHMA
6
DELISTED
Chiasma, Inc. Common Stock
CHMA
$7.49M 4.45%
2,080,595
– –
TARA icon
7
Protara Therapeutics
TARA
$230M
$3.83M 2.28%
50,447
– –
ADAP
8
DELISTED
Adaptimmune Therapeutics
ADAP
$3.39M 2.02%
250,000
– –
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$3.03M 1.8%
273,417
– –
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.81B
$2.91M 1.73%
38,100
– –
CLLS
11
Cellectis
CLLS
$276M
$2.82M 1.68%
100,000
– –
AUPH icon
12
Aurinia Pharmaceuticals
AUPH
$2B
$2.65M 1.58%
400,434
– –
SRRA
13
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.46M 1.46%
36,111
– –
AVEO
14
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.32M 0.78%
40,000
– –
IMDZ
15
DELISTED
Immune Design Corp.
IMDZ
$1.2M 0.71%
352,300
– –
OCGN icon
16
Ocugen
OCGN
$450M
$473K 0.28%
14,815
– –
ONCT
17
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-2,423
Closed -$5.2M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2018 Portfolio in Review

As of Q3 2018, Abingworth held 17 positions worth $168M, down 3.9% from $175M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Abingworth's Q3 2018 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was Verona Pharma: 901,943 shares worth $11.3M. The largest sale was Sientra, Inc., an estimated $6.18M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

  • Abingworth's largest Q3 2018 buy was Verona Pharma: 901,943 shares worth $11.3M.
  • Abingworth's biggest Q3 2018 reduction was Sientra, Inc., cutting an estimated $6.18M.
  • Abingworth fully exited Oncternal Therapeutics, Inc. Common Stock in Q3 2018, selling an estimated $5.2M.
  • Abingworth's ten largest holdings make up 94% of its $168M portfolio in Q3 2018.
  • Abingworth opened 1 new position and closed 1 in Q3 2018.
  • Abingworth's portfolio value fell 3.9% quarter-over-quarter to $168M.

Based on Abingworth's 13F filing for Q3 2018, filed 14 Nov 2018.